The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 23, 2021

Filed:

May. 18, 2016
Applicant:

Dexcom, Inc., San Diego, CA (US);

Inventors:

Martina Vettoretti, Valla di Riesse P, IT;

Andrea Facchinetti, Trissino, IT;

Giovanni Sparacino, Padua, IT;

Claudio Cobelli, Padua, IT;

Assignee:

DexCom, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G16H 50/20 (2018.01); G16H 50/50 (2018.01); G16H 20/17 (2018.01); G16H 40/60 (2018.01); A61M 5/172 (2006.01);
U.S. Cl.
CPC ...
G16H 50/20 (2018.01); A61M 5/1723 (2013.01); G16H 20/17 (2018.01); G16H 40/60 (2018.01); G16H 50/50 (2018.01); A61M 2205/50 (2013.01); A61M 2230/005 (2013.01); A61M 2230/201 (2013.01);
Abstract

A mathematical model of type 1 diabetes (T1D) patient decision-making can be used to simulate, in silico, realistic glucose/insulin dynamics, for several days, in a variety of subjects who take therapeutic actions (e.g. insulin dosing) driven by either self-monitoring blood glucose (SMBG) or continuous glucose monitoring (CGM). The decision-making (DM) model can simulate real-life situations and everyday patient behaviors, Accurate submodels of SMBG and CGM measurement errors are incorporated in the comprehensive DM model. The DM model accounts for common errors the patients are used to doing in their diabetes management, such as miscalculations of meal carbohydrate content, early/delayed insulin administrations and missed insulin boluses. The DM model can be used to assess in silico if/when CGM can safely substitute SMBG in T1D management, to develop and test guidelines for CGM driven insulin dosing, to optimize and individualize off-line insulin therapies and to develop and test decision support systems.


Find Patent Forward Citations

Loading…